### Check for updates

## **OPEN ACCESS**

EDITED BY Yongjun Jiang, The Second Affiliated Hospital of Guangzhou Medical University, China

#### REVIEWED BY Qiankun Cai

The Second Affiliated Hospital of Fujian Medical University, China Yun Zhang, Mianyang Central Hospital, China Alberto Aimo, Sant'Anna School of Advanced Studies, Italy

### \*CORRESPONDENCE Shuanggen Zhu 45353502@qq.com Xinfeng Liu xfliu2@vip.163.com

<sup>†</sup>These authors have contributed equally to this work

#### SPECIALTY SECTION

This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology

RECEIVED 28 July 2022 ACCEPTED 11 August 2022 PUBLISHED 29 August 2022

#### CITATION

Wang F, Wang J, Han Y, Shi X, Xu X, Hou C, Gao J, Zhu S and Liu X (2022) Triglyceride-glucose index and stroke recurrence in elderly patients with ischemic stroke. *Front. Endocrinol.* 13:1005614. doi: 10.3389/fendo.2022.1005614

### COPYRIGHT

© 2022 Wang, Wang, Han, Shi, Xu, Hou, Gao, Zhu and Liu. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Triglyceride-glucose index and stroke recurrence in elderly patients with ischemic stroke

Fang Wang<sup>1†</sup>, Jinjing Wang<sup>1†</sup>, Yunfei Han<sup>1</sup>, Xuan Shi<sup>1</sup>, Xiaohui Xu<sup>1</sup>, Chao Hou<sup>1</sup>, Jie Gao<sup>1</sup>, Shuanggen Zhu<sup>2,3\*</sup> and Xinfeng Liu<sup>1\*</sup>

<sup>1</sup>Department of Neurology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China, <sup>2</sup>Department of Neurology, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, China, <sup>3</sup>Department of Neurology, People's Hospital of Longhua, Shenzhen, China

**Background and purpose:** This study aimed to explore the association between triglyceride–glucose (TyG) index and stroke recurrence in elderly patients with ischemic stroke in China.

**Methods:** We enrolled ischemic stroke patients aged  $\geq$  65 years from the Nanjing Stroke Registry Program. The primary endpoint was defined as recurrent stroke within one year after the index stroke. We used multivariable Cox proportional hazards regression models to investigate the association between TyG index and stroke recurrence. We assessed the discriminative ability of TyG index with the receiver operative characteristic and the area under the curve.

**Results:** A total of 955 patients (median age, 70.0 [67.0, 75.0]; male sex, 67.2%) from the Nanjing Stroke Registry Program were enrolled. During one year follow-up, 97 (10.2%) elderly patients experienced stroke recurrence. In multivariable analyses, the association between TyG index and stroke recurrence remained significant after adjusting for confounders (quartile 4 versus quartile 1; hazard ratio, 2.073, 95% confidence interval, 1.158-3.711; P = 0.014). The restricted cubic spline showed an increasing trend for TyG index and stroke recurrence (*P* for non-linearity = 0.072). The area under the curve to predict stroke recurrence with TyG index was 0.719 (95% confidence interval, 0.666-0.772). Besides, TyG index slightly improved the prediction for stroke recurrence.

**Conclusion:** Elevated TyG index was associated with stroke recurrence in elderly patients with ischemic stroke. Further studies are warranted to assess the role of TyG index in the development of stroke recurrence in the elderly.

KEYWORDS

TyG index, ischemic, stroke, elderly, recurrence

# Introduction

Stroke is a leading course of mortality and disability worldwide (1). Due to multiple risk factors, ischemic stroke increases with advancing age and is associated with poor prognosis in elderly patients (2). Prior studies reported that over 75% of strokes occurred in the elderly and added a heavy economic burden (3). Furthermore, elderly patients have an increased risk of vascular events compared with younger adults (4). With a life expectancy of a least five years ahead, it is warranted to identify elderly patients with higher risk of stroke recurrence (5).

Insulin resistance (IR) is a pathological state caused by increased insulin sensitivity and the precursor of diabetes mellitus (6). Previous studies revealed that IR promotes stroke progression and is associated with poor prognoses (7–9). The golden standard measurement for IR, hyperinsulinemiceuglycemic clamp, is not commonly used in clinical practice due to the cost and complexity (10). Notably, triglyceride– glucose (TyG) index, which is derived from fasting blood glucose and triglyceride, is a convenient surrogate marker of IR (11). Prior studies suggested that TyG index is associated with nonalcoholic fatty liver disease (12), acute coronary syndrome (13), and hyperuricemia (14) in elderly patients. However, few studies have investigated the association between TyG index and the risk of stroke recurrence in elderly patients with ischemic stroke.

Hence, we conducted this study to explore the potential role of TyG index in elderly patients with ischemic stroke.

## Methods

The data that support the findings of this study are available from the corresponding author on reasonable request.

## Participants

From January 1 2013 to October 31, 2016, patients with ischemic stroke were continuously enrolled from the Nanjing Stroke Registry Program (15). This study was approved by the ethics review board of Jinling Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Due to the retrospective nature of this study, patient consent was waived.

Patients were included according to the following criterion: (1) diagnosed as ischemic stroke within 14 days of onset, (2) aged  $\geq 65$  years old, (3) examined with a brain computed tomography or magnetic resonance imaging right before or

during admission, (4) finished at least one year follow up or deceased before then. Patients were excluded if they (1) had recurrent events within the first 21days, (2) had missing fasting blood glucose and triglyceride values.

## **Baseline characteristics**

Demographic data, medical history, laboratory data, imaging data, and medications at discharge were all recorded. Stroke severity was assessed with the National Institute of Health Stroke Scale score (16). Stroke subtypes were classified according to the trial of ORG 10172 in Acute Stroke Treatment classification as large-artery atherosclerosis, cardio-embolism, small vessel occlusion, and others (stroke of other determined etiology and stroke of undetermined etiology) (17). Annual family incomes (1 USD = 7.18 RMB; RMB, Chinese currency) and educational years were acquired with the face-to-face questionnaire. Smoking status was classified as non-smokers, former smokers, and current smokers according to the consumption of cigarettes (18). Fasting blood samples were collected within 24 hours after admission. TyG index was calculated as ln [triglyceride (mg/dL) × fasting blood glucose (mg/dL)/2] (19).

## Follow-up and endpoints

The follow-up schedule for each patient was three, six, and twelve months and annually after the discharge. Stroke recurrence was defined as a new neurological deficit or a sudden deterioration of a previous deficit that fits the criterion of ischemic or hemorrhagic stroke, which was confirmed by clinical manifestation, neuroimaging results, death certificates, or other available data at each follow-up. The endpoint was defined as fatal or nonfatal recurrent stroke within one year of the index stroke (15).

## Statistical analysis

Continuous parameters presented as mean  $\pm$  SD or median (interquartile range) were compared using Student t test or Mann-Whitney U test as appropriate. Categorized parameters presented as n (%) were compared with  $\chi 2$  test or Fisher exact test. Comparison of multiple values between subgroups was compared with trend tests, one-way analysis of variance, or Kruskal-Wallis H test as appropriate. Multiple imputation method with chain equations was performed to deal with missing values.

We performed univariable Cox proportional hazards regression models to explore the association between baseline characteristics and the risk of stroke recurrence. To assess the association between TyG index and stroke recurrence, we adjusted model 1 with age and sex. Model 2 was further adjusted for hypertension, diabetes mellitus, smoking status, drinking, coronary heart disease, atrial fibrillation, antiplatelet drug, anticoagulant, statin, antihypertensive drug and hypoglycemic agent. Model 3 was adjusted for variables with the significance level of P < 0.1 in the univariable analysis with the back-ward selection method except for fasting blood glucose and triglyceride which were included in TyG index. We found no violations of the proportional-hazards assumption with the Schoenfeld residuals test. We also performed the competing risk analysis by accounting for the competing risk of death with the Fine and Gray method.

We explored the pattern of the association between TyG index and stroke recurrence risk with the restricted cubic spline with four knots (at 5th, 35th, 65th, and 95th percentiles) adjusted for the variables finally included in the model 3 (20). The discriminative ability of TyG index was assessed with the receiver operative characteristic and the corresponding area under the curve. Besides, we used the net improvement index (NRI) and integrated discrimination improvement (IDI) to assess the improvement of the model performance after adding TyG index into models (21).

All statistical tests were conducted with R statistical software version 4.1.0. (R Foundation, Vienna, Austria) and a two-sided P value < 0.05 was considered to be statistically significant.

# **Results**

## **Baseline characteristics**

A total of 955 elderly patients (median age, 70.0 [67.0, 75.0]; male sex, 67.2%) with ischemic stroke were included in the present study after excluding 63 patients without fasting blood glucose and triglyceride values and 37 patients without follow-up information or experienced recurrence within first 21 days. Patients with stroke recurrence had lower levels of high density lipoprotein (P = 0.005), higher levels of homocysteine (P = 0.002), fasting blood glucose (P < 0.002) 0.001), systolic blood pressure (P = 0.015), and TyG index (P =0.006), higher proportions of large-artery atherosclerosis and cardio-embolism (P = 0.029), lower annal family income (P =0.039, Table 1. Across different quartiles of TyG index, patients with higher TyG index had higher levels of body mass index (P < 0.001), fasting blood glucose (P < 0.001) and blood urea nitrogen (P =0.044), higher proportions of hypertension (P = 0.001), antihypertensive drug (P < 0.001), diabetes mellitus (P < 0.001), hypoglycemic agent (P = 0.016), dyslipidemia (P < 0.001), smoking (P = 0.001) and stroke recurrence (P = 0.017, Supplementary)Table 1; P = 0.036, Figure 1), and lower proportion of male sex (P < 0.001,Supplementary Table 1).

# Association between TyG index and stroke recurrence

During one year follow-up, 97 (10.2%) patients experienced stroke recurrence, which included 79 (81.4%) ischemic and 18 (18.6%) hemorrhagic recurrent stroke, and 164 (17.1%) patients died. Univariable analysis revealed that age (hazard ratio [HR], 1.041; 95% confidence interval [CI], 1.004-1.078; P = 0.029), triglyceride (HR, 1.263; 95% CI, 1.133-1.408, P < 0.001), high density lipoprotein (HR, 0.306; 95% CI, 0.129-0.724, P = 0.007), homocysteine (HR, 1.024; 95% CI, 1.014-1.035, P < 0.001), fasting blood glucose (HR, 1.133; 95% CI, 1.0067-1.203, P < 0.001), creatine (HR, 1.003; 95% CI, 1.000-1.007, P = 0.041), TyG index (HR, 1.861; 95% CI, 1.400-2.475, P < 0.001), TOAST (small-vessel occlusion versus large-artery atherosclerosis; HR, 0.302; 95% CI, 0.121-0.758, P = 0.011) and annual family income (>15021 versus 1-1502; HR, 0.259; 95% CI, 0.078-0.866, P = 0.028; Supplementary Table 2).

# The ability of the TyG index to predict stroke recurrence

In multivariable analyses, the association between TyG index and stroke recurrence remained significant after adjusting for confounders in model 1 (quartile 4 versus quartile 1; HR, 2.220, 95% CI, 1.251-3.940; P = 0.006), model 2 (quartile 4 versus quartile 1; HR, 2.229, 95% CI, 1.153-4.309; *P* = 0.017), and model 3 (quartile 4 versus quartile 1; HR, 2.073, 95% CI, 1.158-3.711; P = 0.014; Figure 2). The restricted cubic spline showed an increasing trend for TyG index and stroke recurrence (P for nonlinearity = 0.072, Supplementary Figure 1) after adjusting for covariables in the model 3. The area under the curve to predict stroke recurrence with TyG index was 0.719 (95% CI, 0.666-0.772, Figure 3). The association remained significant in the competing risk analysis accounting for the risk of death (Supplementary Table 3). Furthermore, adding TyG index into model 3 slightly improved the prediction of stroke recurrence (NRI (continuous), 0.142; 95% CI, 0.026-0.264, P = 0.020; NRI (categorical) 0.142; 95% CI, -0.032-0.260; *P* = 0.056; IDI, 0.028; 95% CI, 0.010-0.045; *P* = 0.002; Table 2).

# Discussion

In this study, we found that TyG index was associated with stroke recurrence in elderly patients with ischemic stroke. Besides, TyG index slightly improved the prediction for stroke recurrence. These results indicated that TyG index was a surrogate marker and might help identify patients with an increased risk of stroke recurrence in the elderly. TABLE 1 Baseline Characteristics between Patients with or without Stroke Recurrence in the Elderly.

Characteristics	Without recurrence $(N = 858)$	Recurrence $(N = 97)$	P value
Age, years	70 [67, 75]	71 [67, 77]	0.17
Male, n (%)	576 (67.1)	66 (68.0)	0.947
BMI, kg/m (2)	24.2 [22.3, 26.3]	24.8 [22.2, 26.4]	0.517
Systolic blood pressure, mmHg	143 [130, 160]	149 [134, 170]	0.015
Diastolic blood pressure, mmHg	83 [76, 90]	87 [79, 90]	0.103
Hypertension, n (%)	683 (79.6)	81 (83.5)	0.437
Diabetes mellitus, n (%)	287 (33.4)	37 (38.1)	0.417
Dyslipidemia, n (%)	201 (23.4)	28 (28.9)	0.287
Atrial fibrillation, n (%)	120 (14.0)	15 (15.5)	0.809
Coronary heart disease, n (%)	107 (12.5)	11 (11.3)	0.874
Drinking, n (%)	158 (18.4)	15 (15.5)	0.564
Smoking, n (%)			0.804
Nonsmokers	413 (48.1)	44 (45.4)	
Former smokers	112 (13.1)	12 (12.4)	
Current smokers	333 (38.8)	41 (42.3)	
NIHSS, score	3 [1, 7]	4 [2, 8]	0.086
Laboratory results			
Total cholesterol (mmol/L)	4.1 [3.5, 4.8]	4.3 [3.4, 5.0]	0.399
Triglyceride (mmol/L)	1.3 [1.0, 1.7]	1.4 [1.0, 1.9]	0.054
Low density lipoprotein (mmol/L)	2.5 [1.9, 3.0]	2.6 [1.8, 3.1]	0.677
High density lipoprotein (mmol/L)	1.0 [0.9, 1.2]	1.0 [0.8, 1.1]	0.005
Homocysteine (mmol/L)	14.7 [10.7, 19.2]	168 [12.6, 20.4]	0.002
Fasting blood glucose (mmol/L)	52 [46, 63]	56[50,77]	<0.001
Creatine (ummol/L)	67.0 [56.0, 80.0]	70.0 [57.0, 86.0]	0.102
Blood urea nitrogen (mmol/L)	53[45.66]	56[48,68]	0.115
Uric acid, umol/L	326 [259, 393]	331 [277, 402]	0.577
TvG	86[83.90]	88 [83 93]	0.006
TOAST, n (%)	0.0 [0.3, 9.0]	0.0 [0.3, 5.3]	0.029
LAA	401 (467)	50 (51 5)	
CF	100 (117)	16 (16 5)	
SVD	137 (16.0)	5 (5 2)	
Others	220 (25.6)	26 (26.8)	
Education, years, n (%)	220 (25.0)	20 (20.0)	0.869
0-6	361 (42.1)	41 (42.3)	
06-9	298 (34 7)	31 (32.0)	
09-12	114 (13 3)	13 (13.4)	
>12	85 (9.9)	12 (12.4)	
Annual family Income \$ n (%)	03 (7.7)	12 (12.1)	0.039
1-1502	153 (17.8)	22 (22 7)	01005
1502-4506	160 (18.6)	22 (22.7)	
4506-7510	218 (25.4)	31 (32 0)	
7510-15021	241 (28.1)	19 (19.6)	
>15021	86 (10.0)	3 (3 1)	
Medication at discharge n (%)	00 (10.0)	5 (3.1)	
Antiplatelet drug	700 (02.1)	04 (06 0)	0.12
Anticoagulant	(70 (72.1) 53 (6.2)	24 (20)	0.13
Statin	55 (0.2) 914 (04.0)	1 (1.0)	0.000
Antihypertensive drug	014 (74.7)	53 (54.6)	0.529
Lime charmine acount	402 (33.8)	26 (27.1)	0.96/
Hypoglycemic agent	256 (29.8)	36 (37.1)	0.174

BMI, body mass index; CE, cardio-embolism; LAA, large-artery atherosclerosis; NIHSS, National Institute of Health Stroke Scale; SAA, small-vessel occlusion; TyG, triglyceride-glucose index.



Stroke recurrence is common and could cause cumulative disability and cognitive impairment (22). Despite the promotion of secondary preventive drugs and the decreasing trend of the recurrence incidence, approximately 11% of patients still experience recurrence in the early stage after the index stroke (4, 23). Age is the risk factor for stroke recurrence. The incidence of stroke recurrence in the elderly varies from 7.7% to 13.1% due to different exclusion criterion (24, 25). The cumulative incidence in our study (10.2%) was similar to previous reports. Prior studies indicated that elderly patients had markedly higher risks of stroke recurrence than other age groups (23, 26). Besides, elderly patients might have less-effective treatment and poorer outcomes than younger adults (3). Accurate identification of

patients at high risk of stroke recurrence in elderly patients is important to deliver effective secondary prevention and reduce the recurrence risk.

IR is a syndrome linked to metabolic disorders, such as diabetes mellitus, hypertension, obesity, and lipid disorder (27). Subsequently, these disorders are important risk factors for stroke recurrence (28). Previous studies reported that IR played an important role in the development of coronary heart disease, stroke, and cognitive dysfunction, few studies had explored the potential role of IR in the prognosis of ischemic stroke in the elderly (29). TyG index is the combination of fasting glucose and triglyceride and a reliable surrogate marker of IR. In recent years, TyG index has been suggested to assess IR in clinical



#### FIGURE 2

Risk of stroke recurrence in elderly patients for TyG index. CI, confidence interval, TyG, triglyceride-glucose index. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, hypertension, diabetes mellitus, smoking status, drinking, coronary heart disease, atrial fibrillation, antiplatelet drug, anticoagulant, statin, antihypertensive drug and hypoglycemic agent. Model 3: adjusted for variables included in the back-ward selection method: age, high density lipoprotein, homocysteine, annual family income, anticoagulants and stroke subtypes.



practice rather than the golden standard measurement, the hyperinsulinaemic-euglycaemic clamp test, due to the convenience and reliability (19).

Prior studies showed that TyG index was associated with ischemic stroke. A community-based cohort showed that elevated levels of TyG index could independently predict ischemic stroke during an 11-year follow-up in the general population regardless of the sampling time (9). Guo et al. explored the relationship between TyG index and platelet reactivity in patients with acute ischemic stroke and found that elevated TyG index could enhance platelet reactivity. Nam et al. found that TyG index was associated with early recurrent ischemic lesions in a small sample of patients with acute ischemic stroke (30). Unfortunately, studies focusing on the elderly population were limited. A longitudinal study performed among the elderly showed that TyG index had a superior discriminative ability for the occurrence of hypertension over lipid parameters (31). The Northern Shanghai Study revealed that TyG index was associated with macro- and microvascular damage in elderly individuals (32). In our study, we found that TyG index was associated with stroke recurrence and traditional risk factors

such as hypertension and diabetes mellitus in the elderly. TyG index might help identify high risk patients who might benefit from interventions for IR including weight control, physical activity and healthy diets.

The mechanism underlying the association between TyG index and stroke recurrence might be explained as follows. First, IR could affect platelet adhesion, aggregation, and activation and was associated with artery stenosis and occlusion (33, 34). Second, IR might result in chronic inflammation (35), endothelium dysfunction (36), and the formation of foam cells (37). Previous studies suggested that TyG index was related to arterial stiffness in the elderly and thus might contribute to stroke recurrence (38). Third, beyond the specific setting of diabetes, TyG index was also associated with subclinical atherosclerosis (39), coronary atherosclerosis in the general population (40), and carotid plaque stability in nondiabetic adults (41), which were important predictors of ischemic events (42). Fourth, IR might coexist with a cluster of traditional risk factors, such as hypertension, obesity, and diabetes mellitus (9), and contribute to stroke recurrence development.

TABLE 2	Reclassification	Indexes for	<b>Regression</b>	Models.
---------	------------------	-------------	-------------------	---------

Indexes	Estimate (95% CI)	P value
NRI (continuous)	0.142 (0.026-0.264)	0.02
NRI (categorical)	0.142 (-0.032-0.260)	0.056
IDI	0.028 (0.010-0.045)	0.002

CI, confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification improvement.

Besides, we found that homocysteine, stroke subtypes, and family income were associated with stroke recurrence in the elderly. Zhang et al. performed a prospective cohort and found that elevated homocysteine can predict stroke recurrence and mortality in patients with stroke (43). Shi et al. found that homocysteine was associated with stroke recurrence in patients with large-vessel atherosclerosis (44). Large-vessel atherosclerosis is the most common subtype in the Chinese population (45). Lange et al. found that patients with atherosclerosis in the internal carotid artery, intracranial and posterior circulation had an increased risk of stroke recurrence (46). Besides, Flach et al. reported that cardio-embolic stroke also had a higher risk of recurrence (47). Socioeconomic status was also associated with stroke recurrence. Chen et al. suggested that patients with lower socioeconomic status might have less access to acute interventions and were more disobedient to the secondary prevention treatments (48). Our results were in agreement with these previous findings.

However, our study had several limitations. First, this was a retrospective analysis of a prospective database that included patients aged  $\geq$  65 years, which might generate sampling bias. Second, socioeconomic status information was collected by questionnaires, which might generate information bias. Third, we selected stroke recurrence within one year as the endpoint because of the higher recurrence rate within one year and the lower rate of patients without follow-up (49), however, longterm follow-up information was still warranted in the future. Forth, limited by the study design, the time-varying change of TyG index after discharge was not provided, which might provide more information. Fifth, we lacked information about transient ischemic attacks and the patterns of adherence or persistence of medication after discharge, however, we provided medication at discharge instead. Finally, although TyG index was validated to be correlated with the hyperinsulinaemic-euglycaemic clamp test, we were unable to compare the performance of the hyperinsulinaemiceuglycaemic clamp test in our study because of the retrospective nature.

In conclusion, the results of our study showed that elevated TyG index was associated with stroke recurrence in elderly patients with ischemic stroke. Further studies are warranted to assess the role of TyG index in the development of stroke recurrence in the elderly.

## Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

# **Ethics statement**

The studies involving human participants were reviewed and approved by the ethics review board of Jinling Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

# Author contributions

FW, JW, and YH contributed to conception and design of the study. FW, XS, and CH organized the database. FW and XX performed the statistical analysis. FW wrote the first draft of the manuscript. SZ and JG wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

# Funding

The project was supported by National Natural Science Foundation of China (NO. U20A20357, 81901248, 81870946, and 81530038), High Level Project of Medicine in Longhua, ShenZhen (HLPM201907020102), and Construction Funds of Key Medical Disciplines in Longhua District, ShenZhen (MKD202007090208).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fendo.2022.1005614/full#supplementary-material

# References

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics–2014 update: a report from the American heart association. *Circulation* (2014) 129:e28–292. doi: 10.1161/01.cir.0000441139.02102.80

2. Guo Y, Wang H, Tian Y, Wang Y, Lip GY. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. an analysis of 425,600 Chinese individuals without prior stroke. *Thromb Haemost* (2016) 115:184–92. doi: 10.1160/TH15-07-0577

3. Chen R-L, Balami JS, Esiri MM, Chen L-K, Buchan AM. Ischemic stroke in the elderly: an overview of evidence. *Nat Rev Neurology* (2010) 6:256–65. doi: 10.1038/nrneurol.2010.36

4. Castilla-Guerra L, Fernández-Moreno M del C, Alvarez-Suero J. Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia. *Eur J Intern Med* (2009) 20:586–90. doi: 10.1016/j.ejim.2009.06.005

5. Kaplan RC, Tirschwell DL, Longstreth WT Jr., Manolio TA, Heckbert SR, Lefkowitz D, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. *Neurology* (2005) 65:835–42. doi: 10.1212/01.wnl.0000176058.09848.bb

6. Gray SM, Meijer RI, Barrett EJ. Insulin regulates brain function, but how does it get there? *Diabetes* (2014) 63:3992-7. doi: 10.2337/db14-034

7. Pan Y, Jing J, Chen W, Zheng H, Jia Q, Mi D, et al. Post-glucose load measures of insulin resistance and prognosis of nondiabetic patients with ischemic stroke. *J Am Heart Assoc* (2017) 6:e004990. doi: 10.1161/JAHA.116.004990

8. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. *Neurology* (2002) 59:809–15. doi: 10.1212/ WNL.59.6.809

9. Wang A, Wang G, Liu Q, Zuo Y, Chen S, Tao B, et al. Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up. *Cardiovasc Diabetol* (2021) 20:46. doi: 10.1186/s12933-021-01238-1

10. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. *Lancet* (2005) 366:1640–9. doi: 10.1016/S0140-6736 (05)67663-5

11. Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, González-Nava V, Díaz González-Colmenero A, Solis RC, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: A systematic review. *Int J Endocrinol* (2020) 2020:4678526. doi: 10.1155/2020/4678526

12. Huanan C, Sangsang L, Amoah AN, Yacong B, Xuejiao C, Zhan S, et al. Relationship between triglyceride glucose index and the incidence of non-alcoholic fatty liver disease in the elderly: a retrospective cohort study in China. *BMJ Open* (2020) 10:e039804. doi: 10.1136/bmjopen-2020-039804

13. Jiao Y, Su Y, Shen J, Hou X, Li Y, Wang J, et al. Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study. *Cardiovasc Diabetol* (2022) 21:3. doi: 10.1186/s12933-021-01443-v

14. Dong J, Yang H, Zhang Y, Hu Q. Triglyceride-glucose index is a predictive index of hyperuricemia events in elderly patients with hypertension: a cross-sectional study. *Clin Exp Hypertens* (2022) 44:34–9. doi: 10.1080/10641963.2021.1984499

15. Liu X, Xu G, Wu W, Zhang R, Yin Q, Zhu W. Subtypes and one-year survival of first-ever stroke in Chinese patients: The nanjing stroke registry. *Cerebrovasc Dis* (2006) 22:130–6. doi: 10.1159/000093241

16. Brott T, Adams HPJr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. *Stroke* (1989) 20:864–70. doi: 10.1161/01.STR.20.7.864

17. Adams HPJr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. trial of org 10172 in acute stroke treatment. *Stroke* (1993) 24:35-41. doi: 10.1161/01.STR.24.1.35

18. Ramanujam R, Hedstrom AK, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, et al. Effect of smoking cessation on multiple sclerosis prognosis. *JAMA Neurol* (2015) 72:1117–23. doi: 10.1001/jamaneurol.2015.1788

19. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. *Metab Syndr Relat Disord* (2008) 6:299–304. doi: 10.1089/met.2008.0034

20. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med (1989) 8:551–61. doi: 10.1002/sim.4780080504

21. Pencina MJ, D'Agostino RBSr, D'Agostino RBJr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* (2008) 27:157–72. doi: 10.1002/sim.2929

22. Kiyohara Y, Kubo M, Kato I, Tanizaki Y, Tanaka K, Okubo K, et al. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the hisayama study. *Stroke* (2003) 34:2343-7. doi: 10.1161/01.STR.0000091845.14833.43

23. Bergström L, Irewall A-L, Söderström L, Ögren J, Laurell K, Mooe T. Oneyear incidence, time trends, and predictors of recurrent ischemic stroke in Sweden from 1998 to 2010: An observational study. *Stroke* (2017) 48:2046–51. doi: 10.1161/ STROKEAHA.117.016815

24. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. *Stroke*. (2011) 42:1489–94. doi: 10.1161/STROKEAHA.110.602615

25. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MSV. Recurrent stroke and cardiac risks after first ischemic stroke: the northern Manhattan study. *Neurology* (2006) 66:641–6. doi: 10.1212/01.wnl.0000201253.93811.f6

26. Giang KW, Björck L, Ståhl CH, Nielsen S, Sandström TZ, Jern C, et al. Trends in risk of recurrence after the first ischemic stroke in adults younger than 55 years of age in Sweden. *Int J Stroke* (2016) 11:52–61. doi: 10.1177/1747493015607519

27. DeFronzo RA, Ferrannini E. Insulin resistance. a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care* (1991) 14:173–94. doi: 10.2337/diacare.14.3.173

28. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart Association/American stroke association. *Stroke* (2014) 45:2160–236. doi: 10.1161/STR.00000000000024

29. Bas DF, Ozdemir AO, Colak E, Kebapci N. Higher insulin resistance level is associated with worse clinical response in acute ischemic stroke patients treated with intravenous thrombolysis. *Transl Stroke Res* (2016) 7:167–71. doi: 10.1007/s12975-016-0453-y

30. Nam K-W, Kwon H-M, Lee Y-S. High triglyceride-glucose index is associated with early recurrent ischemic lesion in acute ischemic stroke. *Sci Rep* (2021) 11:15335. doi: 10.1038/s41598-021-94631-5

31. Zhu B, Wang J, Chen K, Yan W, Wang A, Wang W, et al. A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the reaction study. *Cardiovasc Diabetol* (2020) 19:112. doi: 10.1186/s12933-020-01077-6

32. Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, et al. Association between macroand microvascular damage and the triglyceride glucose index in communitydwelling elderly individuals: the northern shanghai study. *Cardiovasc Diabetol* (2019) 18:95. doi: 10.1186/s12933-019-0898-x

33. Moore SF, Williams CM, Brown E, Blair TA, Harper MT, Coward RJ, et al. Loss of the insulin receptor in murine megakaryocytes/platelets causes thrombocytosis and alterations in IGF signalling. *Cardiovasc Res* (2015) 107:9– 19. doi: 10.1093/cvr/cvv132

34. Randriamboavonjy V, Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. *Diabetes Care* (2009) 32:528–30. doi: 10.2337/dc08-1942

35. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest (2006) 116:1793–801. doi: 10.1172/JCI29069

36. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. *Circulation* (2005) 112:32–8. doi: 10.1161/CIRCULATIONAHA.104.520130

37. Oh J, Riek AE, Darwech I, Funai K, Shao J, Chin K, et al. Deletion of macrophage vitamin d receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. *Cell Rep* (2015) 10:1872–86. doi: 10.1016/j.celrep.2015.02.043

38. Su Y, Wang S, Sun J, Zhang Y, Ma S, Li M, et al. Triglyceride glucose index associated with arterial stiffness in Chinese community-dwelling elderly. *Front Cardiovasc Med* (2021) 8:737899. doi: 10.3389/fcvm.2021.737899

39. Baydar O, Kilic A, Okcuoglu J, Apaydin Z, Can MM. The triglycerideglucose index, a predictor of insulin resistance, is associated with subclinical atherosclerosis. *Angiology* (2021) 72:994–1000. doi: 10.1177/00033197211007719 40. Aimo A, Chiappino S, Clemente A, Della Latta D, Martini N, Georgiopoulos G, et al. The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population. *Eur J Prev Cardiol* (2022) 29 (5):e203–4. doi: 10.1093/eurjpc/zwab164

41. Wang A, Tian X, Zuo Y, Zhang X, Wu S, Zhao X. Association between the triglyceride-glucose index and carotid plaque stability in nondiabetic adults. *Nutr Metab Cardiovasc Dis* (2021) 31:2921–8. doi: 10.1016/j.numecd.2021.06.019

42. Rosińska J, Ambrosius W, Maciejewska J, Narożny R, Kozubski W, Łukasik M. Association of platelet-derived microvesicles and their phenotypes with carotid atherosclerosis and recurrent vascular events in patients after ischemic stroke. *Thromb Res* (2019) 176:18–26. doi: 10.1016/j.thromres.2019.01.014

43. Zhang W, Sun K, Chen J, Liao Y, Qin Q, Ma A, et al. High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. *Clin Sci (Lond)* (2009) 118:187–94. doi: 10.1042/CS20090142

44. Shi Z, Liu S, Guan Y, Zhang M, Lu H, Yue W, et al. Changes in total homocysteine levels after acute stroke and recurrence of stroke. *Sci Rep* (2018) 8:6993. doi: 10.1038/s41598-018-25398-5

45. Ornello R, Degan D, Tiseo C, Di Carmine C, Perciballi L, Pistoia F, et al. Distribution and temporal trends from 1993 to 2015 of ischemic stroke subtypes: A systematic review and meta-analysis. *Stroke* (2018) 49:814–9. doi: 10.1161/STROKEAHA.117.020031

46. Lange MC, Ribas G, Scavasine V, Ducci RD-P, Mendes DC, Zétola V de HF, et al. Stroke recurrence in the different subtypes of ischemic stroke. the importance of the intracranial disease. *Arq Neuropsiquiatr* (2018) 76:649–53. doi: 10.1590/0004-282x20180095

47. Flach C, Muruet W, Wolfe CDA, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: A population-base cohort study. *Stroke* (2020) 51:2435–44. doi: 10.1161/STROKEAHA.120.028992

48. Chen J, Zhao N, Ruan Y, Zheng K, Xu P, Xia Y, et al. Socioeconomic status and the risk of stroke recurrence in Chinese patients. *Neuroepidemiology* (2019) 53 (3–4):180–6. doi: 10.1159/000501276

49. Fitzek S, Leistritz L, Witte OW, Heuschmann PU, Fitzek C. The Essen stroke risk score in one-year follow-up acute ischemic stroke patients. *Cerebrovasc Dis* (2011) 31:400–7. doi: 10.1159/000323226